Lv1
58 积分 2024-02-01 加入
Discovery of a Highly Potent and Selective Tyrosine Kinase 2 (TYK2) Degrader with In Vivo Therapeutic Efficacy in a Murine Psoriasis Model
14小时前
已完结
Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery
14小时前
已完结
First-in-human phase I results of APG-2449, a novel FAK and third-generation ALK/ ROS1 tyrosine kinase inhibitor (TKI), in patients (pts) with second-generation TKI-resistant ALK/ROS1+ non–small cell lung cancer (NSCLC) or mesothelioma
15小时前
已关闭
Development of a Practical and Scalable Manufacturing Process for Ciprofol
9天前
已完结
Skin Cancer after Ruxolitinib or Belumosudil
12天前
已完结
Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design
13天前
已完结
Development of Tricyclic 4,5-Dihydro-3H-pyrrolo[2,3-c]quinolin-4-ones as Potent Autotaxin Inhibitors for Pulmonary Fibrosis Treatment In Vivo
16天前
已完结
Absolute Bioavailability, Mass Balance, and Metabolic Profiling Assessment of [14C]‐Belumosudil in Healthy Men: A Phase 1, Open‐Label, 2‐Part Study
16天前
已完结
Structural Insights into the Interactions of Belumosudil with Rho-Associated Coiled-Coil Containing Protein Kinases 1 and 2 Based on Molecular Docking, Molecular Dynamics Simulations, and Free Energy Calculations
22天前
已完结
Rho kinase inhibitors: a patent review (2012 – 2013)
22天前
已完结
皖公网安备34019202002308
